Surgical Science Sweden AB (publ) (SUS)
Free
No email, no account, no signup.
Pulling latest news for Surgical Science Sweden AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
HOLD
Sentiment
5/10
Risk
7/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Surgical Science Sweden AB develops VR-based simulators and software for surgical training, including robotic surgery, endoscopy and ultrasound. It sells to both education customers (hospitals/universities) and industry customers via OEM/license agreements.
Exchange
Nasdaq First North Growth Market Stockholm
Sector
MedTech – VR surgical training simulators
Market Cap
$155M
Market sentiment
Sentiment is neutral to slightly negative, driven by concerns about 2026 OEM/license revenue and a large share price drawdown over the past year. Debate centers on whether the large cash position makes it a bargain or a value trap until growth is re-proven.
Why HOLD ?
- **Hold** given the strong balance sheet and structural market growth.
- However, **2026 revenue/margin visibility is weak** due to the Intuitive impact.
- Wait for **evidence in upcoming reports** that Educational Products and cost actions can offset the gap.
- Wait for the Q1 report; consider a small add (up to ~10%) only after confirmed stabilization in license revenue/margins.
Recent News
- The 2025 annual report was published (confirming previously communicated figures and a strong net cash position), followed by the AGM notice and an invitation to the Q1 presentation/teleconference (May 20). The market continues to price in the previously communicated 2026 license revenue shortfall linked to Intuitive.
Bull case
- **Oversold share price** after a steep decline may trigger a technical rebound.
- **Strong net cash** provides downside support and flexibility.
Unlock to read more →
Bear case
- **License revenue may drop** as the Intuitive impact starts to show.
Unlock to read more →
Catalysts
21 May 2026 — Annual General Meeting (AGM)
Dilution Risk
Assessment: Low
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Surgical Science Sweden AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.